IPSEN, OOO

🇷🇺Russia

Country: 🇷🇺Russia

Ownership: -

Established: 1929-01-01

Employees: 5.7K

Market Cap: $9.8B

Website: https://www.ipsen.com/

Clinical Trials

Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours

Completed

Conditions: Gastroenteropancreatic Neuroendocrine Tumours

First Posted Date: 2016-06-02

Last Posted Date: 2020-06-02

Lead Sponsor: Ipsen

Target Recruit Count: 156

Registration Number: NCT02788565

Locations: 🇸🇪
Skane University Hospital, Lund, Sweden
🇸🇪
Uppsala University Hospital, Uppsala, Sweden

Community-based Neuroendocrine Tumor (NET) Research Study

Completed

Conditions: Gastroenteropancreatic Neuroendocrine Tumors

First Posted Date: 2016-04-06

Last Posted Date: 2020-06-26

Lead Sponsor: Ipsen

Target Recruit Count: 100

Registration Number: NCT02730104

Locations: 🇺🇸
Texas Oncology - Denton South, Denton, Texas, United States
🇺🇸
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸
Illinois Cancer Specialists, Arlington Heights, Illinois, United States

and more 9 locations

Efficacy of Diosmectite (Smecta®) in the Symptomatic Treatment of Acute Diarrhoea in Adults

Phase 4

Completed

Conditions: Acute Diarrhoea

Interventions: Drug: Smecta
Drug: Smecta placebo

First Posted Date: 2016-03-09

Last Posted Date: 2020-11-05

Lead Sponsor: Ipsen

Target Recruit Count: 858

Registration Number: NCT02704091

Locations: 🇩🇿
CHU BEN BADIS Constantine, Constantine, Algeria
🇹🇳
CSB Zouhour, Sousse, Tunisia
🇪🇬
Cairo University, Cairo, Egypt

and more 58 locations

Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg

Terminated

Conditions: Acromegaly

First Posted Date: 2016-03-03

Last Posted Date: 2018-12-21

Lead Sponsor: Ipsen

Target Recruit Count: 4

Registration Number: NCT02698384

Locations: 🇫🇷
Hopital Larrey, Toulouse, France
🇫🇷
Hoptial Nord, Amiens, France
🇫🇷
Hopital Albert Michallon, La Tronche, France

and more 7 locations

Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.

Phase 2

Completed

Conditions: Neuroendocrine Tumours

Interventions: Drug: Lanreotide (Autogel formulation) and Temozolomide

First Posted Date: 2016-03-03

Last Posted Date: 2020-10-01

Lead Sponsor: Ipsen

Target Recruit Count: 40

Registration Number: NCT02698410

Locations: 🇮🇹
Oncologia Medica - Istituto Tumori Regina Elena San Gallicano, Roma, Italy
🇮🇹
Oncologia Medica - Istituto Oncologico del Mediterraneo - IOM, Viagrande, Catania, Italy
🇮🇹
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) S.r.l., IRCCS, Meldola, Italy

and more 7 locations

Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: telotristat etiprate

First Posted Date: 2016-02-17

Last Posted Date: 2019-01-25

Lead Sponsor: Ipsen

Target Recruit Count: 24

Registration Number: NCT02683577

Locations: 🇷🇴
ARENSIA Exploratory Medicine, Bucharest, Romania

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours

Phase 3

Terminated

Conditions: Neuroendocrine Tumors in Lung

Interventions: Drug: Lanreotide (Autogel formulation)
Drug: Placebo
Drug: Best Supportive Care

First Posted Date: 2016-02-17

Last Posted Date: 2022-07-06

Lead Sponsor: Ipsen

Target Recruit Count: 77

Registration Number: NCT02683941

Locations: 🇺🇸
Roswell Park Cancer Center, Buffalo, New York, United States
🇺🇸
Arizona Oncology Associates, Tucson, Arizona, United States
🇫🇷
CHU de Rennes - Hôpital Pontchaillou, Rennes, France

and more 54 locations

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2

Phase 3

Terminated

Conditions: Urinary Incontinence
Overactive Bladder

Interventions: Biological: Botulinum toxin type A
Drug: Placebo

First Posted Date: 2016-01-21

Last Posted Date: 2022-09-28

Lead Sponsor: Ipsen

Target Recruit Count: 258

Registration Number: NCT02660359

Locations: 🇨🇴
Asociacion IPS Medicos Internistas de Caldas, Manizales, Colombia
🇨🇱
Clínica Uromed, Santiago, Chile
🇨🇴
Solano & Terront Servicios Medicos LTDA- Unidad Integral de Endocrinologia, Bogotá, Colombia

and more 79 locations

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1

Phase 3

Terminated

Conditions: Urinary Incontinence
Overactive Bladder

Interventions: Biological: Botulinum toxin type A
Drug: Placebo

First Posted Date: 2016-01-21

Last Posted Date: 2022-09-28

Lead Sponsor: Ipsen

Target Recruit Count: 227

Registration Number: NCT02660138

Locations: 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Urology Clinics of North Texas, Dallas, Texas, United States
🇺🇸
Delaware Valley Urology,IIC, Voorhees, New Jersey, United States

and more 77 locations

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg

Phase 2

Completed

Conditions: Pancreatic Tumours
Midgut Neuroendocrine Tumours

Interventions: Drug: Lanreotide autogel 120 mg

First Posted Date: 2016-01-11

Last Posted Date: 2022-10-03

Lead Sponsor: Ipsen

Target Recruit Count: 99

Registration Number: NCT02651987

Locations: 🇳🇱
Erasmus MC, Rotterdam, Netherlands
🇪🇸
Hospital Universitario Vall D'hebron, Barcelona, Spain
🇧🇪
Erasme Hospital, Bruxelles, Belgium

and more 29 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy